SYK - Stryker Corp Stock Price, Fair Value and News

329.26USD-2.88 (-0.87%)Market Closed

Market Summary

USD329.26-2.88

Market Closed

-0.87%

SYK Alerts

Big jump in Earnings (Y/Y)

SYK Stock Price

View Fullscreen

SYK RSI Chart

SYK Valuation

Market Cap

125.4B

Price/Earnings (Trailing)

37.32

Price/Sales (Trailing)

5.98

EV/EBITDA

28.7

Price/Free Cashflow

43.89

SYK Price/Sales (Trailing)

SYK Profitability

Operating Margin

63.80%

EBT Margin

18.69%

Return on Equity

17.53%

Return on Assets

8.53%

Free Cashflow Yield

2.28%

SYK Fundamentals

SYK Revenue

Revenue (TTM)

21.0B

Rev. Growth (Yr)

9.73%

Rev. Growth (Qtr)

-9.84%

SYK Earnings

Earnings (TTM)

3.4B

Earnings Growth (Yr)

33.11%

Earnings Growth (Qtr)

-31.06%

Breaking Down SYK Revenue

Last 7 days

0.4%

Last 30 days

-5.9%

Last 90 days

-2.9%

Trailing 12 Months

16.1%

How does SYK drawdown profile look like?

SYK Financial Health

Current Ratio

1.71

Debt/Equity

0.56

Debt/Cashflow

0.32

SYK Investor Care

Dividend Yield

0.93%

Dividend/Share (TTM)

3.05

Shares Dilution (1Y)

0.51%

Diluted EPS (TTM)

8.76

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	21.0B	0	0	0
2023	19.0B	19.5B	19.9B	20.5B
2022	17.4B	17.6B	17.9B	18.4B
2021	14.7B	16.2B	16.7B	17.1B
2020	15.0B	14.1B	14.2B	14.4B
2019	13.9B	14.2B	14.5B	14.9B
2018	12.7B	13.0B	13.3B	13.6B
2017	11.8B	12.0B	12.1B	12.4B
2016	10.1B	10.5B	10.9B	11.3B
2015	9.7B	9.8B	9.8B	9.9B
2014	9.1B	9.3B	9.5B	9.7B
2013	8.7B	8.8B	8.9B	9.0B
2012	8.5B	8.5B	8.5B	8.7B
2011	7.5B	7.8B	8.1B	8.3B
2010	6.9B	7.0B	7.2B	7.3B
2009	6.7B	6.6B	6.6B	6.7B
2008	0	6.2B	6.5B	6.7B
2007	0	0	0	6.0B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Stryker Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 01, 2024	boehnlein glenn s	sold (taxes)	-196,852	336	-585	vp, chief financial officer
May 01, 2024	menon viju	sold (taxes)	-218,388	336	-649	group president
May 01, 2024	fink m kathryn	sold (taxes)	-47,110	336	-140	vp, chief hr officer
May 01, 2024	becker yin c	sold (taxes)	-49,802	336	-148	vp, chief corp affairs officer
Mar 21, 2024	fink m kathryn	acquired	-	-	83.00	vp, chief hr officer
Mar 21, 2024	fletcher robert s	sold (taxes)	-791,146	353	-2,240	vp, chief legal officer
Mar 21, 2024	boehnlein glenn s	acquired	-	-	256	vp, chief financial officer
Mar 21, 2024	menon viju	sold (taxes)	-1,216,390	353	-3,444	group president
Mar 21, 2024	stiles spencer s	acquired	-	-	203	group president
Mar 21, 2024	becker yin c	sold (taxes)	-279,726	353	-792	vp, chief corp affairs officer

Which funds bought or sold SYK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	OPPENHEIMER & CO INC	added	3.67	1,425,710	7,393,950	0.12%
May 07, 2024	Algebris (UK) Ltd	added	15.21	254,356	876,931	0.33%
May 07, 2024	FORSTA AP-FONDEN	added	10.22	7,433,720	30,867,400	0.26%
May 07, 2024	Keudell/Morrison Wealth Management	unchanged	-	370,437	2,269,610	0.69%
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	reduced	-19.84	-1,369,850	31,168,000	-%
May 07, 2024	Arizona State Retirement System	added	2.04	6,319,440	35,116,700	0.24%
May 07, 2024	Reynders McVeigh Capital Management, LLC	reduced	-0.64	6,034,000	38,232,000	2.20%
May 07, 2024	Meeder Advisory Services, Inc.	added	5.92	415,627	1,979,540	0.20%
May 07, 2024	KCM INVESTMENT ADVISORS LLC	added	20.56	179,758	587,623	0.02%
May 07, 2024	Swiss National Bank	reduced	-4.18	46,431,800	366,495,000	0.26%

Are Funds Buying or Selling SYK?

Are funds buying SYK calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SYK

No. of Funds

SYK Alerts

Big jump in Earnings (Y/Y)

Unveiling Stryker Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	8.20%	31,149,173	SC 13G/A
Feb 12, 2024	greenleaf trust	4.9%	18,723,395	SC 13G/A
Jan 29, 2024	blackrock inc.	6.6%	24,924,572	SC 13G/A
Feb 14, 2023	price t rowe associates inc /md/	4.0%	14,929,245	SC 13G/A
Feb 10, 2023	greenleaf trust	5.3%	19,869,434	SC 13G/A
Feb 09, 2023	vanguard group inc	7.99%	30,246,178	SC 13G/A
Feb 01, 2023	blackrock inc.	6.5%	24,494,206	SC 13G/A
Feb 14, 2022	price t rowe associates inc /md/	5.5%	21,156,776	SC 13G/A
Feb 11, 2022	greenleaf trust	5.4%	20,452,972	SC 13G/A
Feb 10, 2022	vanguard group inc	7.60%	28,652,681	SC 13G/A

Recent SEC filings of Stryker Corp

View All Filings

Date Filed	Form Type	Document
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 01, 2024	10-Q	Quarterly Report
Apr 30, 2024	8-K	Current Report
Mar 26, 2024	DEF 14A	DEF 14A
Mar 26, 2024	DEFA14A	DEFA14A
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading

Peers (Alternatives to Stryker Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	182.6B	40.3B	-5.05%	-4.82%	32.45	4.53	-2.84%	-3.08%
BDX	67.4B	19.7B	-3.45%	-6.52%	50.6	3.42	4.82%	-17.56%
ALGN	20.6B	3.9B	-14.54%	-9.65%	44.54	5.26	5.72%	46.72%
BAX	18.2B	14.9B	-15.38%	-17.01%	6.88	1.22	2.98%	207.68%
MID-CAP
ATR	10.0B	3.5B	7.32%	25.05%	31.94	2.82	6.16%	35.06%
HSIC	9.3B	12.5B	0.39%	-2.78%	24.01	0.75	-0.61%	-18.83%
BIO	7.6B	2.6B	-17.82%	-26.90%	-23.72	2.94	-6.25%	-68.62%
XRAY	5.8B	3.9B	-13.74%	-32.04%	-61.76	1.47	0.23%	91.03%
AXNX	3.4B	387.1M	-0.59%	20.47%	-215.56	8.87	30.82%	65.57%
PDCO	2.3B	6.6B	-1.26%	-0.69%	11.98	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.92%	-14.34%	-1.85	0.4	7.94%	-1661.78%
ANIK	423.5M	169.3M	11.74%	12.93%	-5.51	2.5	7.49%	-244.90%
ANGO	236.7M	324.0M	-10.59%	-34.33%	-1.23	0.73	-3.19%	-337.41%
APYX	45.4M	52.3M	-10.27%	-60.90%	-2.43	0.87	17.61%	19.28%
AEMD	3.3M	3.7M	-25.00%	250.00%	-0.27	0.88	5.77%	8.23%

Stryker Corp News

Latest updates

Stryker Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-9.8%	5,243	5,815	4,909	4,996	4,778	5,202	4,479	4,493	4,275	4,701	4,160	4,294	3,953	4,262	3,737	2,764	3,588	4,131	3,587	3,650	3,516
Cost Of Revenue	-9.6%	1,910	2,112	1,751	1,815	1,762	1,966	1,697	1,667	1,541	1,656	1,518	1,522	1,444	1,545	1,276	1,216	1,257	1,428	1,257	1,270	1,233
Gross Profit	-10.0%	3,333	3,703	3,158	3,181	3,016	3,236	2,782	2,826	2,734	3,045	2,642	2,772	2,509	2,717	2,461	1,548	2,331	2,703	2,330	2,380	2,283
Operating Expenses	-3.5%	2,361	2,446	2,227	2,216	2,281	2,422	1,974	2,054	2,287	2,226	2,068	2,040	2,050	1,968	1,602	1,568	1,696	1,759	1,702	1,767	1,755
S&GA Expenses	-5.2%	1,840	1,941	1,701	1,706	1,781	1,751	1,455	1,539	1,710	1,745	1,602	1,505	1,575	1,562	1,244	1,225	1,330	1,380	1,291	1,282	1,403
R&D Expenses	5.1%	368	350	353	346	339	326	364	351	413	331	306	310	288	255	242	233	254	254	246	246	225
EBITDA Margin	3.2%	0.22*	0.22*	0.20*	0.20*	0.19*	0.18*	0.19*	0.17*	0.17*	0.17*	0.17*	0.19*	0.16*	0.18*	0.20*	0.19*	0.22*	0.21*	0.20*	-	-
Income Taxes	62.7%	135	83.00	177	161	87.00	198	-	64.00	63.00	95.00	57.00	70.00	65.00	103	159	-4.00	97.00	211	115	85.00	68.00
Earnings Before Taxes	-24.7%	923	1,226	869	899	679	761	816	720	386	757	495	662	367	671	780	-87.00	590	936	581	565	480
EBT Margin	4.3%	0.19*	0.18*	0.16*	0.16*	0.16*	0.15*	0.15*	0.13*	0.13*	0.13*	0.13*	0.15*	0.12*	0.14*	0.16*	0.14*	0.18*	0.17*	0.16*	-	-
Net Income	-31.1%	788	1,143	692	738	592	563	816	656	323	662	438	592	302	568	621	-83.00	493	725	466	480	412
Net Income Margin	3.8%	0.16*	0.15*	0.13*	0.14*	0.14*	0.13*	0.14*	0.12*	0.12*	0.12*	0.11*	0.13*	0.10*	0.11*	0.12*	0.11*	0.14*	0.14*	0.24*	-	-
Free Cashflow	-97.3%	37.00	1,383	902	536	315	815	751	386	84.00	794	803	772	369	1,072	760	511	447	536	466	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-1.3%	39,402	39,912	38,042	37,409	36,830	36,884	35,983	36,032	36,137	34,631	34,145	33,698	33,455	34,330	32,286	31,483	29,440	30,167	26,659	26,354	25,937
Current Assets	-5.0%	11,892	12,518	11,045	10,151	10,155	10,275	9,318	8,825	8,725	10,017	9,460	9,032	8,979	9,707	13,545	12,801	10,736	11,058	8,566	8,185	7,888
Cash Equivalents	-21.6%	2,330	2,971	1,860	1,401	1,671	1,844	1,420	1,044	1,458	2,944	2,563	2,241	2,238	2,943	7,083	6,539	3,964	4,337	1,948	1,754	1,674
Inventory	3.8%	5,026	4,843	4,883	4,593	4,333	3,995	3,883	3,749	3,525	3,314	3,434	3,431	3,473	3,494	3,459	3,442	3,359	2,980	3,269	3,198	3,064
Net PPE	1.4%	3,260	3,215	3,106	3,082	3,037	2,970	2,798	2,803	2,793	2,833	2,746	2,738	2,710	2,752	2,529	2,527	2,607	2,567	2,460	2,387	2,297
Goodwill	0.7%	15,351	15,243	15,138	15,172	14,849	14,880	14,993	15,115	15,228	12,918	12,893	12,802	12,803	12,778	9,128	9,074	9,025	9,069	8,704	8,762	114
Liabilities	-5.1%	20,230	21,319	20,137	20,048	19,935	20,268	19,520	20,358	21,091	19,754	19,967	19,878	19,953	21,246	19,300	18,729	16,325	17,360	14,344	14,411	14,244
Current Liabilities	-12.2%	6,955	7,921	7,458	6,584	5,866	6,303	4,571	4,404	4,408	4,549	4,449	4,252	3,953	5,041	4,689	4,405	4,162	4,400	3,921	3,946	3,713
Long Term Debt	-0.9%	10,807	10,901	10,382	11,149	11,857	11,857	12,751	13,374	13,885	12,472	12,629	12,734	13,059	13,230	12,008	11,811	9,404	10,231	7,889	7,974	7,950
LT Debt, Non Current	-100.0%	-	10,901	10,382	11,149	11,857	11,857	12,751	13,374	13,885	12,472	12,629	12,734	13,059	13,230	12,008	11,811	9,404	10,231	7,889	7,974	7,950
Shareholder's Equity	3.1%	19,172	18,593	17,905	38.00	38.00	16,616	16,463	13,933	38.00	14,877	14,178	38.00	38.00	38.00	12,986	1,706	38.00	11,748	12,315	1,569	37.00
Retained Earnings	2.9%	17,254	16,771	15,933	15,526	15,072	14,765	14,486	13,933	13,540	13,480	13,081	12,881	12,525	12,462	12,129	11,725	12,024	11,748	11,238	10,967	10,683
Additional Paid-In Capital	2.6%	2,257	2,200	2,183	2,127	2,090	2,034	2,028	1,989	1,947	1,890	1,875	1,844	1,806	1,741	1,736	1,706	1,676	1,628	1,593	1,569	1,538
Accumulated Depreciation	2.2%	3,198	3,129	3,049	3,005	2,933	2,835	2,736	2,746	2,739	2,665	2,694	2,624	2,496	2,430	2,310	2,248	2,169	2,147	2,143	2,091	2,045
Shares Outstanding	0.4%	381	380	380	379	379	378	378	378	378	377	377	377	376	376	375	375	375	374	374	-	-
Float	-	-	-	-	109,723	-	-	-	70,965	-	-	-	91,942	-	-	-	63,413	-	-	-	71,863	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-86.6%	204	1,528	1,050	688	445	1,003	889	529	203	1,000	933	878	452	1,237	829	620	591	735	629	514	313
Share Based Compensation	117.5%	87.00	40.00	52.00	39.00	74.00	28.00	33.00	36.00	71.00	30.00	34.00	39.00	68.00	27.00	29.00	30.00	56.00	32.00	32.00	28.00	35.00
Cashflow From Investing	-168.4%	-408	-152	-145	-533	-132	-162	72.00	-152	-2,682	-314	-247	-202	-96.00	-4,352	-69.00	-117	-163	-719	-186	-247	-303
Cashflow From Financing	-46.2%	-418	-286	-422	-405	-481	-446	-543	-753	993	-288	-348	-676	-1,053	-1,057	-242	2,056	-768	2,363	-225	-188	-1,947
Dividend Payments	-100.0%	-	285	285	285	284	263	263	263	262	237	238	237	238	216	216	216	215	193	195	195	195
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	307

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SYK Income Statement

2024-03-31

CONSOLIDATED STATEMENTS OF EARNINGS (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net sales	$ 5,243	$ 4,778
Cost of sales	1,910	1,762
Gross profit	3,333	3,016
Research, development and engineering expenses	368	339
Selling, general and administrative expenses	1,840	1,781
Amortization of intangible assets	153	161
Total operating expenses	2,361	2,281
Operating income	972	735
Other income (expense), net	(49)	(56)
Earnings before income taxes	923	679
Income taxes	135	87
Net earnings	$ 788	$ 592
Net earnings per share of common stock:
Basic (in dollars per share)	$ 2.07	$ 1.56
Diluted (in dollars per share)	$ 2.05	$ 1.54
Weighted-average shares outstanding (in millions):
Basic (in shares)	380.4	379.0
Effect of dilutive employee stock compensation (in shares)	4.7	4.2
Diluted (in shares)	385.1	383.2
Cash dividends declared per share of common stock (in dollars per share)	$ 0.80	$ 0.75

SYK Balance Sheet

2024-03-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 2,330	$ 2,971
Marketable securities	77	82
Accounts receivable, less allowance of $175 ($182 in 2023)	3,473	3,765
Inventories:
Materials and supplies	1,232	1,242
Work in process	372	330
Finished goods	3,422	3,271
Total inventories	5,026	4,843
Prepaid expenses and other current assets	986	857
Total current assets	11,892	12,518
Property, plant and equipment:
Land, buildings and improvements	1,686	1,692
Machinery and equipment	4,772	4,652
Total property, plant and equipment	6,458	6,344
Less allowance for depreciation	3,198	3,129
Property, plant and equipment, net	3,260	3,215
Goodwill	15,351	15,243
Other intangibles, net	4,509	4,593
Noncurrent deferred income tax assets	1,641	1,670
Other noncurrent assets	2,749	2,673
Total assets	39,402	39,912
Current liabilities
Accounts payable	1,246	1,517
Accrued compensation	778	1,478
Income taxes	444	391
Dividends payable	305	304
Accrued expenses and other liabilities	2,124	2,137
Current maturities of debt	2,058	2,094
Total current liabilities	6,955	7,921
Long-term debt, excluding current maturities	10,807	10,901
Income taxes	565	567
Other noncurrent liabilities	1,903	1,930
Total liabilities	20,230	21,319
Shareholders' equity
Common stock, $0.10 par value	38	38
Additional paid-in capital	2,257	2,200
Retained earnings	17,254	16,771
Accumulated other comprehensive loss	(377)	(416)
Total shareholders' equity	19,172	18,593
Total liabilities and shareholders' equity	$ 39,402	$ 39,912

About Stryker Corp

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

CEO	Mr. Kevin A. Lobo
WEBSITE	stryker.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	51000

Stryker Corp Frequently Asked Questions

What is the ticker symbol for Stryker Corp? What does SYK stand for in stocks?

SYK is the stock ticker symbol of Stryker Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Stryker Corp (SYK)?

As of Wed May 08 2024, market cap of Stryker Corp is 125.43 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SYK stock?

You can check SYK's fair value in chart for subscribers.

What is the fair value of SYK stock?

You can check SYK's fair value in chart for subscribers. The fair value of Stryker Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Stryker Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SYK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Stryker Corp a good stock to buy?

The fair value guage provides a quick view whether SYK is over valued or under valued. Whether Stryker Corp is cheap or expensive depends on the assumptions which impact Stryker Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SYK.

What is Stryker Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, SYK's PE ratio (Price to Earnings) is 37.32 and Price to Sales (PS) ratio is 5.98. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SYK PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Stryker Corp's stock?

In the past 10 years, Stryker Corp has provided 0.163 (multiply by 100 for percentage) rate of return.